open access

Vol 70, No 1 (2019)
Original papers
Published online: 2018-10-23
Submitted: 2018-09-20
Accepted: 2018-09-27
Get Citation

Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation — first three years of Polish experience

Elżbieta Petriczko, Tomasz Jackowski, Anita Horodnicka-Józwa, Beata Wikiera, Anna Noczyńska, Maria Korpal-Szczyrska, Dorota Birkholz-Walerzak, Ewa Małecka-Tendera, Barbara Kalina-Fraska, Maria Kalina, Ewa Barg, Iwona Beń-Skowronek, Leszek Szewczyk, Maciej Hilczer, Joanna Smyczyńska, Renata Stawerska, Andrzej Lewiński, Katarzyna Ziora, Artur Bossowski, Edyta Pietrewicz, Beata Pyrżak, Andrzej Kędzia, Mieczysław Szalecki, Agnieszka Kilian, Mieczysław Walczak
DOI: 10.5603/EP.a2018.0074
·
Pubmed: 30351442
·
Endokrynologia Polska 2019;70(1):20-27.

open access

Vol 70, No 1 (2019)
Original papers
Published online: 2018-10-23
Submitted: 2018-09-20
Accepted: 2018-09-27

Abstract

Introduction: The objective of this study was to analyse the effects of the first three years of treatment with recombinant human insulinlike growth factor 1 (rhIGF-1) in patients from the Polish population.

Material and methods: Twenty-seven children (22 boys and five girls) aged 2.8 to 16.0 years old were qualified for treatment with rhIGF-1 (mecasermin) in different treatment centres, according to Polish criteria: body height below –3.0 SD and IGF-1 concentration below percentile 2.5 with normal growth hormone (GH) levels. Mecasermin initial dose was 40 μg/kg bw twice a day and was subsequently increased to an average of 100 μg/kg bw twice a day. Body height, height velocity, weight, body mass index (BMI), and adverse events were measured.

Results: Mecasermin treatment resulted in a statistically significant increase in body height (1.45 ± 1.06 SD; p < 0.01) and height velocity in comparison with pre-treatment values. The biggest change in height velocity happened during the first year and diminished during subsequent years. Body weight and BMI also increased significantly after treatment (1.16 ± 0.76 SD and 0.86 ± 0.75 SD, respectively; p < 0.01). Eight patients reported adverse events. These were mild and temporary and did not require treatment modification except in two patients.

Conclusions: Treatment with rhIGF-1 was effective and safe in Polish patients with primary IGF-1 deficiency. It had a clear beneficial effect on the height of the patients and significantly accelerated the height velocity, particularly in the first year of treatment.

Abstract

Introduction: The objective of this study was to analyse the effects of the first three years of treatment with recombinant human insulinlike growth factor 1 (rhIGF-1) in patients from the Polish population.

Material and methods: Twenty-seven children (22 boys and five girls) aged 2.8 to 16.0 years old were qualified for treatment with rhIGF-1 (mecasermin) in different treatment centres, according to Polish criteria: body height below –3.0 SD and IGF-1 concentration below percentile 2.5 with normal growth hormone (GH) levels. Mecasermin initial dose was 40 μg/kg bw twice a day and was subsequently increased to an average of 100 μg/kg bw twice a day. Body height, height velocity, weight, body mass index (BMI), and adverse events were measured.

Results: Mecasermin treatment resulted in a statistically significant increase in body height (1.45 ± 1.06 SD; p < 0.01) and height velocity in comparison with pre-treatment values. The biggest change in height velocity happened during the first year and diminished during subsequent years. Body weight and BMI also increased significantly after treatment (1.16 ± 0.76 SD and 0.86 ± 0.75 SD, respectively; p < 0.01). Eight patients reported adverse events. These were mild and temporary and did not require treatment modification except in two patients.

Conclusions: Treatment with rhIGF-1 was effective and safe in Polish patients with primary IGF-1 deficiency. It had a clear beneficial effect on the height of the patients and significantly accelerated the height velocity, particularly in the first year of treatment.

Get Citation

Keywords

insulin-like growth factor-1 (IGF-1); growth hormone insensitivity; IGF-1 deficiency; short stature; growth-promoting therapy; mecasermin; Poland

About this article
Title

Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation — first three years of Polish experience

Journal

Endokrynologia Polska

Issue

Vol 70, No 1 (2019)

Pages

20-27

Published online

2018-10-23

DOI

10.5603/EP.a2018.0074

Pubmed

30351442

Bibliographic record

Endokrynologia Polska 2019;70(1):20-27.

Keywords

insulin-like growth factor-1 (IGF-1)
growth hormone insensitivity
IGF-1 deficiency
short stature
growth-promoting therapy
mecasermin
Poland

Authors

Elżbieta Petriczko
Tomasz Jackowski
Anita Horodnicka-Józwa
Beata Wikiera
Anna Noczyńska
Maria Korpal-Szczyrska
Dorota Birkholz-Walerzak
Ewa Małecka-Tendera
Barbara Kalina-Fraska
Maria Kalina
Ewa Barg
Iwona Beń-Skowronek
Leszek Szewczyk
Maciej Hilczer
Joanna Smyczyńska
Renata Stawerska
Andrzej Lewiński
Katarzyna Ziora
Artur Bossowski
Edyta Pietrewicz
Beata Pyrżak
Andrzej Kędzia
Mieczysław Szalecki
Agnieszka Kilian
Mieczysław Walczak

References (13)
  1. Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther. 2009; 26(1): 40–54.
  2. Filus A, Zdrojewicz Z. Insulinopodobny czynnik wzrostu-1 (IGF-1) — budowa i rola w organizmie człowieka [Insulin-like growth factor-1 (IGF-1) — structure and the role in the human body. Pediatr Endocrinol Diabetes Metab. 2015; 20(4): 161–169.
  3. Iranpoor H, Omidinia E, Vatankhah V. Expression of Recombinant Human Insulin-like Growth Factor Type 1 (rhIGF-1) in Escherichia coli. Avicenna J Med Biotechnol. 2015; 7(3): 101–105.
  4. Petriczko E, Wikiera B, Horodnicka-Józwa A, et al. A two year observation of the process of applying recombinant IGF-1 to treat short stature in children with primary IGF-1 deficiency — case reports of 3 patients. Pediatr Endocrinol Diabetes Metab. 2011; 17(4): 233–238.
  5. Backeljauw P, Bang P, Clayton PE. Diagnosis and management of primary insulin-like growth factor-I deficiency: current perspectives and clinical update. Pediatr Endocrinol Rev. 2010; 7 Suppl 1: 154–171.
  6. Hardin DS. Statement 6: patients who are unresponsive to GH therapy should be given a trial of IGF-I. Pediatr Endocrinol Rev. 2008; 5(Suppl 3): 857–860.
  7. Coutant R, Dörr HG, Gleeson H. Diagnosis of endocrine disease: limitations of the IGF1 generation test in children with short stature. Eur J Endocrinol. 2012; 166(3): 351–357.
  8. Ranke MB, Savage MO, Chatelain PG. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res. 1999; 51(3): 128–134.
  9. Chernausek SD, Backeljauw PF, Frane J. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007; 92(3): 902–910.
  10. Guevara-Aguirre J, Rosenbloom AL, Vasconez O. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab. 1997; 82(2): 629–633.
  11. Richmond EJ, Rogol AD. Recombinant human insulin-like growth factor-I therapy for children with growth disorders. Adv Ther. 2008; 25(12): 1276–1287.
  12. Midyett LK, Rogol AD, Van Meter QL, et al. MS301 Study Group. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2010; 95(2): 611–619.
  13. Ahn SY, Pi LQ, Hwang ST, et al. Effect of IGF-I on Hair Growth Is Related to the Anti-Apoptotic Effect of IGF-I and Up-Regulation of PDGF-A and PDGF-B. Ann Dermatol. 2012; 24(1): 26–31.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl